Sanuwave Health EBITDA 2010-2024 | SNWVD
Sanuwave Health ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Sanuwave Health Annual EBITDA
(Millions of US $) |
| 2023 |
$7 |
| 2022 |
$-3 |
| 2021 |
$-10 |
| 2020 |
$-24 |
| 2019 |
$-9 |
| 2018 |
$-4 |
| 2017 |
$-3 |
| 2016 |
$-3 |
| 2015 |
$-4 |
| 2014 |
$-6 |
| 2013 |
$-6 |
| 2012 |
$-6 |
| 2011 |
$-8 |
| 2010 |
$-11 |
| 2009 |
$-8 |
Sanuwave Health Quarterly EBITDA
(Millions of US $) |
| 2024-06-30 |
$4 |
| 2024-03-31 |
$1 |
| 2023-12-31 |
$3 |
| 2023-09-30 |
$1 |
| 2023-06-30 |
$3 |
| 2023-03-31 |
$0 |
| 2022-12-31 |
$1 |
| 2022-09-30 |
$-1 |
| 2022-06-30 |
$-2 |
| 2022-03-31 |
$-1 |
| 2021-12-31 |
$-0 |
| 2021-09-30 |
$-2 |
| 2021-06-30 |
$-3 |
| 2021-03-31 |
$-4 |
| 2020-12-31 |
$-12 |
| 2020-09-30 |
$-6 |
| 2020-06-30 |
$-3 |
| 2020-03-31 |
$-3 |
| 2019-12-31 |
$-2 |
| 2019-09-30 |
$-2 |
| 2019-06-30 |
$-2 |
| 2019-03-31 |
$-2 |
| 2018-12-31 |
$-1 |
| 2018-09-30 |
$-3 |
| 2018-06-30 |
$-1 |
| 2018-03-31 |
$0 |
| 2017-12-31 |
$-1 |
| 2017-09-30 |
$-1 |
| 2017-06-30 |
$-1 |
| 2017-03-31 |
$-1 |
| 2016-12-31 |
$-1 |
| 2016-09-30 |
$-1 |
| 2016-06-30 |
$-1 |
| 2016-03-31 |
$-1 |
| 2015-12-31 |
$-1 |
| 2015-09-30 |
$-1 |
| 2015-06-30 |
$-1 |
| 2015-03-31 |
$-1 |
| 2014-12-31 |
$-1 |
| 2014-09-30 |
$-1 |
| 2014-06-30 |
$-2 |
| 2014-03-31 |
$-2 |
| 2013-12-31 |
$-1 |
| 2013-09-30 |
$-2 |
| 2013-06-30 |
$-2 |
| 2013-03-31 |
$-1 |
| 2012-12-31 |
$-2 |
| 2012-09-30 |
$-1 |
| 2012-06-30 |
$-1 |
| 2012-03-31 |
$-2 |
| 2011-12-31 |
$-2 |
| 2011-09-30 |
$-2 |
| 2011-06-30 |
$-2 |
| 2011-03-31 |
$-2 |
| 2010-12-31 |
$-4 |
| 2010-09-30 |
$-2 |
| 2010-06-30 |
$-2 |
| 2010-03-31 |
$-3 |
| 2009-12-31 |
$-2 |
| 2009-09-30 |
$-2 |
| 2009-06-30 |
$-1 |
| 2009-03-31 |
$-2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED PRODUCTS |
$0.056B |
$0.020B |
|
SANUWAVE Health, Inc. is engaged in the development and commercialization of non-invasive, biological response-activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures. The Company's product candidates include its proprietary PACE technology applicable in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions; and dermaPACE for treatment of the skin and subcutaneous soft tissue. The Company's products help in activating biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration. SANUWAVE Health, Inc. is based in Alpharetta, USA.
|
